Project Grant R44AI191943
Award Date 9/25/25
Completion Date 8/31/28
Dollars Obligated $980K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This $497,069 Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), supports research to investigate the mechanisms of cyanide-induced neurotoxicity and purine dysregulation. The principal investigator at Beth Israel Deaconess Medical Center, Inc. (Bidmc) will utilize mass spectrometry-based metabolite profiling and animal models to elucidate the metabolite disturbances downstream of cyanide exposure. The research...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $195,625 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Colorado Boulder. The grant supports research to structurally and functionally characterize phosphoethanolamine (PEtN) transferases, enzymes responsible for conferring resistance to cationic antimicrobial peptides (CAMPs) and the antibiotic colistin in multidrug-resistant Gram-negative...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
- This $481,250 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant will fund the development of new antimicrobial small molecule compounds that recruit the immune system to target bacteria. Key activities include the biochemical, biophysical, and cell biology characterization of these chimeric molecules formed by joining bacterial binding agents with...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Optimeos Life Sciences, Inc., a biotechnology company in New Jersey. The grant supports the development of an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies such as ADA-SCID. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $171,254 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Nimml Institute Inc., a 501(c)(3) non-profit research organization in Blacksburg, Virginia. The grant, effective from December 1, 2024 to November 30, 2026, aims to elucidate novel immunometabolic mechanisms that intercept bacterial toxin internalization and processing to suppress cell damage caused by Clostridioides difficile...